21:32 , Sep 19, 2018 |  BC Innovations  |  Translation in Brief

To eat and not to eat

A Nature Communications paper published last month by Forty Seven Inc. (NASDAQ:FTSV) co-founder Irving Weissman and colleagues at Stanford University highlights a new strategy for boosting “eat me” signals on cancer cells that could complement...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Bavencio, Inlyta combo meets PFS endpoint in first-line RCC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab plus Inlyta axitinib met the primary endpoint of improving progression-free survival (PFS) vs. Sutent sunitinib in the Phase III JAVELIN Renal 101 trial to treat...
22:08 , Sep 11, 2018 |  BC Extra  |  Clinical News

Bavencio, Inlyta combo meets PFS endpoint in first-line RCC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab plus Inlyta axitinib met the primary endpoint of improving progression-free survival vs. Sutent sunitinib in the Phase III JAVELIN Renal 101 trial to treat previously...
21:16 , Aug 31, 2018 |  BC Extra  |  Company News

Management tracks: Medigene, Merck KGaA

Medigene AG (Xetra:MDG1) said CFO Thomas Taapken has resigned. Medigene is seeking a successor. Taapken, who joined the cancer immunotherapy company in January 2017, will continue to advise Medigene as a consultant through the end...
18:13 , Aug 31, 2018 |  BC Week In Review  |  Financial News

ApoGen expands series A to $11M

Drug-resistant cancer company ApoGen Biotechnologies Inc. raised an additional $4 million on Aug. 23 from M Ventures and existing investors in its series A round, bringing the round's total to $11 million. M Ventures is...
20:34 , Aug 17, 2018 |  BC Extra  |  Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

China's State Medical Insurance Administration announced 18 cancer drugs that will be included in 2018 medical insurance access negotiations. Companies with drugs on the list will now enter into negotiations to include the drugs on...
18:44 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Vaccinex raises $40M IPO

Vaccinex Inc. (NASDAQ:VCNX) raised $40 million through the sale of 3.3 million shares at $12 in an IPO underwritten by Oppenheimer, BTIG and Ladenburg. The offering values the company at $137.7 million. Vaccinex priced the offering...
16:07 , Aug 10, 2018 |  BioCentury  |  Finance

Missing the obvious

Despite the vast amount of venture money being poured into innovation in healthcare, women’s health still remains an underserved market with significant untapped potential. The importance of this for public health is often overlooked in favor...
19:40 , Aug 9, 2018 |  BC Extra  |  Financial News

Vaccinex down following $40M IPO

Vaccinex Inc. (NASDAQ:VCNX) lost $0.62 to $11.38 Thursday after it raised $40 million through the sale of 3.3 million shares at $12 in an IPO underwritten by Oppenheimer, BTIG and Ladenburg. The offering values the...
21:35 , Aug 3, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 8 profitable biotechs and pharmas are slated to report earnings this week. (A) Formerly Valeant Pharmaceuticals International Inc. CompanyDatePre/post mkt2Q18 EPS est2Q17 EPSExpected chgBausch Health Companies Inc. (TSX:BHC; NYSE:BHC) (A)8/7Pre$0.80$1.03-22%Jazz Pharmaceuticals plc...